18
Participants
Start Date
March 31, 2021
Primary Completion Date
November 30, 2024
Study Completion Date
November 30, 2025
TL-895
TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
KRT-232
KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
Medical University Vienna, Department of Internal Medicine I, Clinical Department of Hematology and Hemostaseology, Vienna
Westmead Hospital, Sydney
Ordensklinikum Linz GmbH Elisabethinen, Linz
University of Sunshine Coast-Sippy Downs, Sippy Downs
Weill Cornell Medical College, New York
Paoli-Calmettes Institute, Marseille
Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia
University Hospital Hamburg-Eppendorf, Department of Internal Medicine II, Hamburg
Gachon University Gil Medical Center, Incheon
Hannover Medical School, Center for Internal Medicine, Clinic of Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Hanover
Georgia Cancer Center, Augusta
Polyclinic S. Orsola-Malpighi, Operative Unit of Hematology, Bologna
University Hospital of Nantes, Nantes
University Duisburg-Essen, University Hospital Essen, Department of Internal Medicine, Essen
University of Cincinnati, Cincinnati
University Clinical Hospital of Valencia, Department of Hematology and Medical Oncology, Valencia
Hospital Universitario y Politécnico de La Fe, Valencia
Romagnolo Scientific Institute of Meldola (IRST) S.r.l., Department of Oncology and Clinical and Experimental Haematology, Meldola
South Lyon Hospital Center, Lyon
Karmanos Cancer Institute, Detroit
Claude Huriez Hospital, Lille
University Hospital - Ospedali Riuniti Umberto I - GM Lancisi - G Salesi of Ancona, Haematology Clinic, Ancona
Northwestern Memorial Hospital, Chicago
Rush University Medical Center, Division of Hematology Oncology and Cell Therapy, Chicago
Saint-Louis Hospital, Paris
UT Southwestern Medical Center, Harold C. Simmons Cancer Center, Dallas
Keck School of Medicine, Los Angeles
University of California, Irvine Medical Center, Orange
Seattle Cancer Care Alliance, Seattle
Hospital Center Universitaire De Nice, Nice
University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology, Halle
University Hospital Jena, Clinic of Internal Medicine II, Department of Hematology and Medical Oncology, Jena
Seoul National University Hospital, Department of Hemato-Oncology, Seoul
University Hospital Germans Trias i Pujol, Department of Clinical Hematology, Badalona
University Hospital Vall d'Hebron, Barcelona
Collaborators (1)
Kartos Therapeutics, Inc.
INDUSTRY
Telios Pharma, Inc.
INDUSTRY